In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 21 to 30 of 40

Sort by

Keyword or reference number: lung cancerRemove Keyword or reference number: lung cancer filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]	Technology appraisal guidance	TBC
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]	Technology appraisal guidance	TBC
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]	Technology appraisal guidance	TBC
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]	Technology appraisal guidance	TBC
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]	Technology appraisal guidance	TBC
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]	Technology appraisal guidance	TBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]	Technology appraisal guidance	TBC
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]	Technology appraisal guidance	TBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007	Technology appraisal guidance	TBC
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]	Technology appraisal guidance	TBC

Results per page

10
25
50
All